| Filed On | Filing |
|---|---|
| 21 Oct 2026 | Proxy statement: special meeting on November 13, 2026 |
| 09 Oct 2026 | PRE 14A |
| 09 Oct 2026 |
Form 4/A: GordonMD Global Investments Lp, 10% owner and 3 others
Acquired 7,172,000 Common Stock Purchase Warrant (Open Market Purchase) |
| 09 Oct 2026 | SCHEDULE 13G/A |
| 05 Oct 2026 | SCHEDULE 13G |
| 02 Oct 2026 |
Form 4: GordonMD Global Investments Lp, 10% owner and 3 others
Bought 5,517,000 shares · Acquired 7,546,766 Common Stock Purchase Warrant (Open Market Purchase) |
| 02 Oct 2026 | SCHEDULE 13G/A |
| 01 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Common Warrants to Purchase up to 49,310,352 Shares of Common Stock |
| 01 Oct 2026 | FORM 424B5 |
| 29 Sep 2026 | FORM 424B5 |
| 29 Sep 2026 | FORM 424B5 |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) |
| 08 Sep 2026 |
Form 4: Civik Thomas, Director
Granted 2,503,050 Stock Option (Right to Buy) |
| 08 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
John Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board |
| 28 Aug 2026 | 424B2 |
| 27 Aug 2026 | EFFECT |
| 20 Aug 2026 |
Form 4: Dupont Jakob, Director
Granted 46,000 Stock Option (Right to Buy) |
| 20 Aug 2026 | S-3 |
| 14 Aug 2026 |
Form 4: Civik Thomas, Director
Granted 250,956 Stock Option (Right to Buy) |
| 13 Aug 2026 | 10-Q |
Loading...
